Aspirin for primary prevention of atherosclerotic cardiovascular events

Aldo L. Schenone; A. Michael Lincoff

doi:10.3949/ccjm.87a.19045

Aspirin for primary prevention of atherosclerotic cardiovascular events

Aldo L. Schenone, A. Michael Lincoff

Research output: Contribution to journal › Review article › peer-review

5 Scopus citations

Abstract

Recent trials evaluated the impact of aspirin for primary prevention of cardiovascular events in patients at intermediate risk, patients with diabetes, and the elderly, and the results have been incorporated into the most recent professional guidelines. For the most part, the role of aspirin in primary prevention remains limited, albeit not adequately tested in those at higher risk.

Original language	English (US)
Pages (from-to)	300-311
Number of pages	12
Journal	Cleveland Clinic journal of medicine
Volume	87
Issue number	5
DOIs	https://doi.org/10.3949/ccjm.87a.19045
State	Published - May 1 2020
Externally published	Yes

ASJC Scopus subject areas

General Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3949/ccjm.87a.19045

Cite this

@article{a1b25c8c02cc46e68e2e7ecf51b62608,

title = "Aspirin for primary prevention of atherosclerotic cardiovascular events",

abstract = "Recent trials evaluated the impact of aspirin for primary prevention of cardiovascular events in patients at intermediate risk, patients with diabetes, and the elderly, and the results have been incorporated into the most recent professional guidelines. For the most part, the role of aspirin in primary prevention remains limited, albeit not adequately tested in those at higher risk.",

author = "Schenone, {Aldo L.} and Lincoff, {A. Michael}",

year = "2020",

month = may,

day = "1",

doi = "10.3949/ccjm.87a.19045",

language = "English (US)",

volume = "87",

pages = "300--311",

journal = "Cleveland Clinic journal of medicine",

issn = "0891-1150",

publisher = "Cleveland Clinic Educational Foundation",

number = "5",

}

TY - JOUR

T1 - Aspirin for primary prevention of atherosclerotic cardiovascular events

AU - Schenone, Aldo L.

AU - Lincoff, A. Michael

PY - 2020/5/1

Y1 - 2020/5/1

N2 - Recent trials evaluated the impact of aspirin for primary prevention of cardiovascular events in patients at intermediate risk, patients with diabetes, and the elderly, and the results have been incorporated into the most recent professional guidelines. For the most part, the role of aspirin in primary prevention remains limited, albeit not adequately tested in those at higher risk.

AB - Recent trials evaluated the impact of aspirin for primary prevention of cardiovascular events in patients at intermediate risk, patients with diabetes, and the elderly, and the results have been incorporated into the most recent professional guidelines. For the most part, the role of aspirin in primary prevention remains limited, albeit not adequately tested in those at higher risk.

UR - http://www.scopus.com/inward/record.url?scp=85084871430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85084871430&partnerID=8YFLogxK

U2 - 10.3949/ccjm.87a.19045

DO - 10.3949/ccjm.87a.19045

M3 - Review article

C2 - 32357985

AN - SCOPUS:85084871430

SN - 0891-1150

VL - 87

SP - 300

EP - 311

JO - Cleveland Clinic journal of medicine

JF - Cleveland Clinic journal of medicine

IS - 5

ER -

Aspirin for primary prevention of atherosclerotic cardiovascular events

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this